TPD & Induced Proximity Summit Leaderboard
  • Saturday, June 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 20

Author

Pharma Journalist 8887 posts 0 comments

Sanofi Licenses Kali’s Tri-Specific Antibody in $1B Deal

Mar 24, 2026
Kali Therapeutics has entered into a licensing agreement with Sanofi for the development of a novel tri-specific T-cell engager, KT501, aimed at treating a broad range of B…
Read More...

LGM Pharma Expands U.S. Manufacturing With $15M Investment

Mar 20, 2026
LGM Pharma has announced a $9 million expansion across its U.S. manufacturing network, marking the second phase of a broader contract development and manufacturing organization (CDMO)…
Read More...

Excalipoint Raises $68.7M to Advance T-Cell Therapies

Mar 20, 2026
Excalipoint Therapeutics has secured an oversubscribed $68.7 million seed financing round to accelerate the development of its next-generation T-cell engager (TCE) therapies, marking…
Read More...

UK Streamlines Drug Approvals to Accelerate Patient Access

Mar 20, 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) have unveiled a new collaborative framework aimed at speeding…
Read More...

Novartis Targets Breast Cancer With Novel PI3Kα Inhibitor Deal

Mar 20, 2026
Novartis has announced a strategic agreement with Synnovation Therapeutics, LLC to acquire SNV4818, an investigational oral therapy designed to treat hormone receptor-positive,…
Read More...

Vir Biotechnology and Astellas Announce $1.71B Partnership, Accelerating Innovation in…

Mar 19, 2026
Another major milestone has reshaped the T‑cell engager landscape. Vir Biotechnology and Astellas Pharma have entered a new global strategic partnership valued at $1.71 billion to…
Read More...

FDA Approves First Oral IL-23 Blocker for Psoriasis

Mar 19, 2026
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), a novel oral therapy for the treatment of moderate-to-severe…
Read More...

Voro, Daiichi Sankyo Partner on Tumor-Activated ADCs

Mar 18, 2026
Voro Therapeutics has entered into a research collaboration with Daiichi Sankyo to develop next-generation antibody-drug conjugates (ADCs) using its proprietary PrimeBody platform. The…
Read More...

Terumo BCT, Taiwan Bio Partner on Treg Manufacturing

Mar 18, 2026
Terumo Blood and Cell Technologies (Terumo BCT) has entered into a strategic collaboration with Taiwan Bio Therapeutics Inc. to advance the manufacturing of regulatory T-cell (Treg)…
Read More...

R1 Therapeutics Launches With $77.5M to Advance Kidney Drug

Mar 18, 2026
R1 Therapeutics has officially launched as a new clinical-stage biopharmaceutical company, backed by an oversubscribed $77.5 million Series A financing and a strategic licensing…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.